RADX:NASDAQ, Radiopharm Theranostics Limited
RADX stock overview
Radiopharm Theranostics Limited (RADX:NASDAQ) closed at $0.760 on November 13, 2026,
down 3.80% on the day.
The stock trades 95.3% below its 52-week high of $16.25
and 3.3% above its 52-week low of $0.736.
Over the past year, it lost 83.2%.
Radiopharm Theranostics Limited is part of the Health Care sector.
Key figures
- Price
- $0.760
- Day change
- -3.80%
- Volume
- 22,059
- Average volume
- 58,754
- Market cap
- 11M+
- 52-week range
- $0.736 – $16.25
- 50-day average
- $1.32
- 200-day average
- $3.49
Price action over the past year
In 252 trading sessions since November 13, 2025, RADX closed higher on 104 days (41%).
Its best day was December 15, 2025 (+149.53%) and its worst was December 16, 2025 (-43.65%).
The stock moved 10% or more in a single session 9 times.
It opened at least 5% above the previous day's high 5 times.
Recent signals
RADX news
-
Nov 9, 2026:
UPDATE – International companies to host live webcasts at Deutsche Bank's Depositary Receipts Virtual Investor Conference on November 12, 2026
-
Nov 5, 2026:
International companies to host live webcasts at Deutsche Bank's Depositary Receipts Virtual Investor Conference on November 12, 2026
-
Nov 4, 2026:
Radiopharm Theranostics Announces Alignment with U.S. FDA on Single Pivotal Phase 3 Trial for RAD101 in Diagnosis of Brain Metastases
-
Nov 2, 2026:
Radiopharm Theranostics Reports Business Update
-
Oct 20, 2026:
GE HealthCare Wins Approval for MINItrace Magni Cyclotron in Europe
-
Oct 5, 2026:
Radiopharm Completes Productive End-of-Phase 2 Meeting with U.S. Food and Drug Administration for Pivotal Development Program of RAD101
-
Sep 30, 2026:
Edison Issues Report on Starpharma (SPL)
-
Sep 14, 2026:
Radiopharm Theranostics Selected for Late-Breaking Oral Presentation of Positive Data from Interim Analysis of U.S. Phase 2b Imaging Trial of RAD101 at 2026 Society of Neuro-Oncology Annual Meeting
About Radiopharm Theranostics Limited
Radiopharm Theranostics Limited engages in the research and development of radiopharmaceutical products for diagnostic and therapeutic uses in areas of high unmet medical needs. It is developing its lead products comprising Nano-mAbs and AVB6 Integrin.
Similar stocks
Find more stocks like RADX with the
Spikes,
Gaps,
Breakouts and
Performance Tracker scanners.
Based on end-of-day data. For information only, not investment advice.